MX2013012905A - Inmunotoxina recombinante dirigida a la mesotelina. - Google Patents
Inmunotoxina recombinante dirigida a la mesotelina.Info
- Publication number
- MX2013012905A MX2013012905A MX2013012905A MX2013012905A MX2013012905A MX 2013012905 A MX2013012905 A MX 2013012905A MX 2013012905 A MX2013012905 A MX 2013012905A MX 2013012905 A MX2013012905 A MX 2013012905A MX 2013012905 A MX2013012905 A MX 2013012905A
- Authority
- MX
- Mexico
- Prior art keywords
- mesothelin
- cells
- present
- cancers
- mesotheliomas
- Prior art date
Links
- 102000003735 Mesothelin Human genes 0.000 title abstract 6
- 108090000015 Mesothelin Proteins 0.000 title abstract 6
- 229940051173 recombinant immunotoxin Drugs 0.000 title abstract 2
- 230000008685 targeting Effects 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 3
- 206010027406 Mesothelioma Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical group C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 239000002254 cytotoxic agent Substances 0.000 abstract 1
- 231100000599 cytotoxic agent Toxicity 0.000 abstract 1
- 230000003013 cytotoxicity Effects 0.000 abstract 1
- 231100000135 cytotoxicity Toxicity 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 210000005033 mesothelial cell Anatomy 0.000 abstract 1
- 210000001672 ovary Anatomy 0.000 abstract 1
- 230000035945 sensitivity Effects 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A61K39/001168—Mesothelin [MSLN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Abstract
La mesotelina es un antígeno de diferenciación presente en la superficie de los cánceres de ovario, mesoteliomas y varios otros tipos de cánceres humanos. Puesto que entre los tejidos normales, la mesotelina está presente solo en las células mesoteliales, representa un buen blanco para la entrega de agentes citotóxicos mediada por anticuerpo. La presente invención está dirigida a mejores inmunotoxinas recombinantes que comprenden anticuerpos anti-mesotelina, incluyendo moléculas Fv con afinidad particularmente alta por la mesotelina, y una mitad de Exotoxina de Pseudomonas, que ha sido modificada para reducir su inmunogenicidad y la sensibilidad a la proteasa, y proporcionan una mejor citotoxicidad para las células que expresan la mesotelina. Las RIT son adecuadas para el tratamiento de cánceres de ovarios, estómago, células escamosas, mesoteliomas y otras células malignas que expresan la mesotelina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161483531P | 2011-05-06 | 2011-05-06 | |
PCT/US2012/036456 WO2012154530A1 (en) | 2011-05-06 | 2012-05-04 | Recombinant immunotoxin targeting mesothelin |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2013012905A true MX2013012905A (es) | 2014-04-25 |
Family
ID=46147033
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013012905A MX2013012905A (es) | 2011-05-06 | 2012-05-04 | Inmunotoxina recombinante dirigida a la mesotelina. |
Country Status (21)
Country | Link |
---|---|
US (1) | US10683362B2 (es) |
EP (1) | EP2704739B1 (es) |
JP (2) | JP6169561B2 (es) |
KR (1) | KR20140036216A (es) |
CN (1) | CN103648525B (es) |
AU (1) | AU2012253896B2 (es) |
BR (1) | BR112013028537A2 (es) |
CA (1) | CA2835070C (es) |
CL (1) | CL2013003182A1 (es) |
CO (1) | CO6862104A2 (es) |
CR (1) | CR20130571A (es) |
EC (1) | ECSP13013067A (es) |
ES (1) | ES2641877T3 (es) |
IL (1) | IL229198A0 (es) |
MA (1) | MA35244B1 (es) |
MX (1) | MX2013012905A (es) |
PE (1) | PE20141454A1 (es) |
RU (1) | RU2600067C2 (es) |
SG (1) | SG194787A1 (es) |
WO (1) | WO2012154530A1 (es) |
ZA (1) | ZA201308270B (es) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2013012905A (es) | 2011-05-06 | 2014-04-25 | Us Gov Health & Human Serv | Inmunotoxina recombinante dirigida a la mesotelina. |
US8932586B2 (en) | 2011-09-06 | 2015-01-13 | Intrexon Corporation | Modified forms of Pseudomonas exotoxin A |
US10450354B2 (en) | 2013-03-12 | 2019-10-22 | Molecular Templates, Inc. | CD20-binding immunotoxins for inducing cellular internalization and methods using same |
WO2014182532A1 (en) * | 2013-05-07 | 2014-11-13 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Mesothelin-specific immunocytokine and use thereof |
US9388222B2 (en) | 2013-10-06 | 2016-07-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modified Pseudomonas exotoxin A |
KR20230028808A (ko) | 2014-01-27 | 2023-03-02 | 몰레큘러 템플레이츠, 인코퍼레이션. | 포유류에 적용하기 위한 탈면역된 시가 독소 a 서브유닛 작동체 폴리펩티드 |
CA2937524A1 (en) * | 2014-02-05 | 2015-08-13 | Molecular Templates, Inc. | Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity |
US11142584B2 (en) | 2014-03-11 | 2021-10-12 | Molecular Templates, Inc. | CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same |
CN106604934A (zh) | 2014-06-11 | 2017-04-26 | 分子模板公司 | 耐受蛋白酶切割的志贺毒素a亚基效应子多肽和包含其的细胞靶向分子 |
EP3795594A1 (en) | 2015-02-05 | 2021-03-24 | Molecular Templates, Inc. | Multivalent cd20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof |
WO2016146833A1 (en) | 2015-03-19 | 2016-09-22 | F. Hoffmann-La Roche Ag | Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance |
PL3303373T3 (pl) | 2015-05-30 | 2020-09-21 | Molecular Templates, Inc. | Deimmunizowane rusztowania podjednostki a toksyny shiga oraz zawierające je cząsteczki nakierowane na komórki |
AR106365A1 (es) * | 2015-10-02 | 2018-01-10 | Hoffmann La Roche | Moléculas biespecíficas de unión a antígeno activadoras de células t |
AU2016329111A1 (en) * | 2015-10-02 | 2018-02-08 | F. Hoffmann-La Roche Ag | Bispecific anti-CEAXCD3 T cell activating antigen binding molecules |
EP3184547A1 (en) | 2015-10-29 | 2017-06-28 | F. Hoffmann-La Roche AG | Anti-tpbg antibodies and methods of use |
BR112018003984A2 (pt) | 2015-12-09 | 2018-09-25 | Hoffmann La Roche | anticorpos |
EP3400246B1 (en) | 2016-01-08 | 2020-10-21 | H. Hoffnabb-La Roche Ag | Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies |
WO2017196847A1 (en) | 2016-05-10 | 2017-11-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens |
WO2017208018A1 (en) | 2016-06-02 | 2017-12-07 | Immunocore Limited | Dosing regimen for gp100-specific tcr - anti-cd3 scfv fusion protein |
EP3464602A4 (en) * | 2016-06-06 | 2020-02-26 | Asclepiumm Taiwan Co., Ltd. | FUSION PROTEINS TO ANTIBODIES FOR ADMINISTRATION OF MEDICINES |
WO2017214182A1 (en) | 2016-06-07 | 2017-12-14 | The United States Of America. As Represented By The Secretary, Department Of Health & Human Services | Fully human antibody targeting pdi for cancer immunotherapy |
EP3494135A1 (en) | 2016-08-02 | 2019-06-12 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof |
EP3608333A1 (en) | 2016-12-07 | 2020-02-12 | Molecular Templates, Inc. | Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation |
WO2018119279A1 (en) | 2016-12-21 | 2018-06-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies specific for flt3 and uses thereof |
MX2019008840A (es) | 2017-01-25 | 2019-09-09 | Molecular Templates Inc | Moleculas con direccion hacia las celulas que comprenden efectores de la sub-unidad a de la toxina shiga desinmunizados y epitopos de las celulas t cd8+. |
CN108624607B (zh) * | 2017-03-16 | 2021-11-16 | 上海恒润达生生物科技股份有限公司 | 靶向mesothelin的嵌合抗原受体并对其双重修饰的方法和用途 |
CN108624608B (zh) * | 2017-03-17 | 2021-11-16 | 上海恒润达生生物科技股份有限公司 | 靶向mesothelin的***嵌合抗原受体的制备方法和用途 |
MX2019011640A (es) | 2017-03-27 | 2020-01-20 | Cidra Corporate Services Llc | Eliminacion de particulas hidrofobas usando dioxido de carbono. |
CN108728458B (zh) * | 2017-04-21 | 2021-11-16 | 上海恒润达生生物科技股份有限公司 | 靶向mesothelin的嵌合抗原受体并联合表达IL-15的方法和用途 |
WO2018213612A1 (en) | 2017-05-18 | 2018-11-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin polypeptides and proteins |
EP3625256A1 (en) | 2017-05-19 | 2020-03-25 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Human monoclonal antibody targeting tnfr2 for cancer immunotherapy |
CN109134660B (zh) * | 2017-06-16 | 2022-07-01 | 上海恒润达生生物科技股份有限公司 | 靶向Mesothelin的嵌合抗原受体并联合表达抗PD1抗体的方法及其用途 |
WO2019005208A1 (en) | 2017-06-30 | 2019-01-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY |
US11795235B2 (en) * | 2017-09-18 | 2023-10-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunotoxins with albumin binding domain |
CN110612117B (zh) | 2018-04-17 | 2024-04-12 | 分子模板公司 | 包含去免疫化的志贺毒素a亚基支架的her2靶向分子 |
CA3105694A1 (en) | 2018-07-12 | 2020-01-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Affinity matured cd22-specific monoclonal antibody and uses thereof |
AU2019317565A1 (en) | 2018-08-08 | 2021-02-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | High affinity monoclonal antibodies targeting glypican-2 and uses thereof |
CA3125484A1 (en) | 2019-01-08 | 2020-07-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cross-species single domain antibodies targeting mesothelin for treating solid tumors |
EP3883971A1 (en) | 2019-01-22 | 2021-09-29 | The United States of America, as represented by the Secretary, Department of Health and Human Services | High affinity monoclonal antibodies targeting glypican-1 and methods of use |
WO2021081052A1 (en) | 2019-10-22 | 2021-04-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | High affinity nanobodies targeting b7h3 (cd276) for treating multiple solid tumors |
BR112023002150A2 (pt) | 2020-08-05 | 2023-05-02 | Dragonfly Therapeutics Inc | Anticorpos direcionando egfr e uso dos mesmos |
WO2022093745A1 (en) | 2020-10-26 | 2022-05-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting sars coronavirus spike protein and uses thereof |
CN112574953A (zh) * | 2020-12-11 | 2021-03-30 | 南通大学 | 一种间皮素嵌合抗原受体外泌体、及其制备方法和应用 |
WO2022232612A1 (en) | 2021-04-29 | 2022-11-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Lassa virus-specific nanobodies and methods of their use |
CN117500831A (zh) | 2021-06-09 | 2024-02-02 | 美国政府(由卫生和人类服务部的部长所代表) | 用于治疗实体瘤的靶向pd-l1的跨物种单结构域抗体 |
CN116023501A (zh) * | 2021-10-25 | 2023-04-28 | 三生国健药业(上海)股份有限公司 | 一种抗her2的免疫毒素分子、及其制备方法与应用 |
WO2023076881A1 (en) | 2021-10-26 | 2023-05-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein |
WO2023107954A1 (en) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
WO2023114980A1 (en) | 2021-12-17 | 2023-06-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin polypeptides, proteins, and chimeric antigen receptors |
WO2023131285A1 (zh) * | 2022-01-07 | 2023-07-13 | 原启生物科技(上海)有限责任公司 | 靶向cldn18.2和msln的嵌合抗原受体及其用途 |
WO2024050399A1 (en) | 2022-09-01 | 2024-03-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
WO1987002671A1 (en) | 1985-11-01 | 1987-05-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5055303A (en) | 1989-01-31 | 1991-10-08 | Kv Pharmaceutical Company | Solid controlled release bioadherent emulsions |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5271961A (en) | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
US5188837A (en) | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
US5254342A (en) | 1991-09-30 | 1993-10-19 | University Of Southern California | Compositions and methods for enhanced transepithelial and transendothelial transport or active agents |
EP1136556B1 (en) | 1991-11-25 | 2005-06-08 | Enzon, Inc. | Method of producing multivalent antigen-binding proteins |
CA2129514A1 (en) | 1992-03-12 | 1993-09-16 | M. Amin Khan | Controlled released acth containing microspheres |
DE69333951D1 (de) | 1992-06-18 | 2006-02-02 | Us Gov Health & Human Serv | Rekombinantes pseudomonas exotoxin mit gesteigerter aktivität |
US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
US5747654A (en) | 1993-06-14 | 1998-05-05 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant disulfide-stabilized polypeptide fragments having binding specificity |
US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
US5888773A (en) | 1994-08-17 | 1999-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Method of producing single-chain Fv molecules |
DE69629580D1 (de) * | 1995-10-13 | 2003-09-25 | Us Gov Health & Human Serv | Immunotoxin enthaltend ein disulfid-stabilisiertes antikörperfragment |
AU703769B2 (en) | 1996-01-05 | 1999-04-01 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Mesothelium antigen and methods and kits for targeting it |
NO961031D0 (no) * | 1996-03-13 | 1996-03-13 | Det Norske Radiumshospital Tum | Fremgangsmåte til å drepe uönskede målceller |
WO1998045322A2 (en) | 1997-04-10 | 1998-10-15 | Royal Netherlands Academy Of Arts And Sciences | Diagnosis method and reagents |
US6211338B1 (en) * | 1997-11-28 | 2001-04-03 | Schering Corporation | Single-chain recombinant complexes of hepatitis C virus NS3 protease and NS4A cofactor peptide |
US6809184B1 (en) | 1997-12-01 | 2004-10-26 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use |
US6296843B1 (en) | 1998-04-03 | 2001-10-02 | The Penn State Research Foundation | Mutagenized IL 13-based chimeric molecules |
MXPA01011950A (es) | 1999-05-27 | 2002-05-06 | Gov Health & Human Serv | Inmunoconjugados que tienen alta afinidad de enlace. |
MXPA04002368A (es) * | 2001-09-12 | 2005-07-25 | Virexx Res Inc | Agente de fase solida para la oclusion vascular con un agente enlazante de plaquetas inmovilizado. |
US7317091B2 (en) * | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US20040091503A1 (en) * | 2002-08-20 | 2004-05-13 | Genitrix, Llc | Lectin compositions and methods for modulating an immune response to an antigen |
US20040223966A1 (en) * | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
US20080125363A1 (en) | 2004-12-14 | 2008-05-29 | Enzon Pharmaceuticals Inc. | Polymer-Linked Pseudomonas Exotoxin Immunotoxin |
RU2007130552A (ru) | 2005-01-10 | 2009-02-20 | Рисерч Дивелопмент Фаундейшн (US) | Рекомбинантные молекулы направленного действия для лечения рака |
ES2386367T3 (es) | 2005-03-10 | 2012-08-17 | Morphotek, Inc. | Anticuerpos anti-mesotelina |
ATE524489T1 (de) | 2005-07-29 | 2011-09-15 | Us Gov Health & Human Serv | Mutierte pseudomonas-exotoxine mit reduzierter antigenität |
AU2006338562A1 (en) | 2005-11-03 | 2007-08-30 | Genentech, Inc. | Therapeutic anti-HER2 antibody fusion polypeptides |
CA2661634C (en) | 2006-09-06 | 2017-03-28 | The Regents Of The University Of California | Selectively targeted antimicrobial peptides and the use thereof |
US8871906B2 (en) | 2007-09-04 | 2014-10-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Deletions in domain II of pseudomonas exotoxin a that remove immunogenic epitopes |
CN102655882B (zh) | 2009-09-11 | 2014-11-19 | 美国政府健康及人类服务部 | 具有降低的免疫原性的改进的假单胞菌外毒素a |
MX2013012905A (es) | 2011-05-06 | 2014-04-25 | Us Gov Health & Human Serv | Inmunotoxina recombinante dirigida a la mesotelina. |
-
2012
- 2012-05-04 MX MX2013012905A patent/MX2013012905A/es not_active Application Discontinuation
- 2012-05-04 US US14/115,131 patent/US10683362B2/en active Active
- 2012-05-04 AU AU2012253896A patent/AU2012253896B2/en active Active
- 2012-05-04 ES ES12722586.0T patent/ES2641877T3/es active Active
- 2012-05-04 JP JP2014509467A patent/JP6169561B2/ja active Active
- 2012-05-04 EP EP12722586.0A patent/EP2704739B1/en active Active
- 2012-05-04 WO PCT/US2012/036456 patent/WO2012154530A1/en active Application Filing
- 2012-05-04 PE PE2013002456A patent/PE20141454A1/es not_active Application Discontinuation
- 2012-05-04 CN CN201280033583.7A patent/CN103648525B/zh active Active
- 2012-05-04 CA CA2835070A patent/CA2835070C/en active Active
- 2012-05-04 KR KR1020137032247A patent/KR20140036216A/ko not_active Application Discontinuation
- 2012-05-04 RU RU2013148919/10A patent/RU2600067C2/ru active
- 2012-05-04 BR BR112013028537A patent/BR112013028537A2/pt not_active IP Right Cessation
- 2012-05-04 SG SG2013081799A patent/SG194787A1/en unknown
-
2013
- 2013-10-31 IL IL229198A patent/IL229198A0/en unknown
- 2013-11-05 ZA ZA2013/08270A patent/ZA201308270B/en unknown
- 2013-11-05 CR CR20130571A patent/CR20130571A/es unknown
- 2013-11-06 CL CL2013003182A patent/CL2013003182A1/es unknown
- 2013-11-21 CO CO13274153A patent/CO6862104A2/es unknown
- 2013-12-04 EC ECSP13013067 patent/ECSP13013067A/es unknown
- 2013-12-06 MA MA36534A patent/MA35244B1/fr unknown
-
2017
- 2017-03-08 JP JP2017043879A patent/JP2017140029A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
PE20141454A1 (es) | 2014-10-23 |
EP2704739A1 (en) | 2014-03-12 |
CL2013003182A1 (es) | 2014-08-22 |
CN103648525A (zh) | 2014-03-19 |
ECSP13013067A (es) | 2015-04-30 |
RU2600067C2 (ru) | 2016-10-20 |
CR20130571A (es) | 2014-02-27 |
EP2704739B1 (en) | 2017-07-12 |
ZA201308270B (en) | 2016-08-31 |
CA2835070C (en) | 2021-07-06 |
MA35244B1 (fr) | 2014-07-03 |
WO2012154530A1 (en) | 2012-11-15 |
SG194787A1 (en) | 2013-12-30 |
IL229198A0 (en) | 2014-01-30 |
JP2017140029A (ja) | 2017-08-17 |
JP6169561B2 (ja) | 2017-07-26 |
NZ617386A (en) | 2015-05-29 |
KR20140036216A (ko) | 2014-03-25 |
US10683362B2 (en) | 2020-06-16 |
US20140154248A1 (en) | 2014-06-05 |
CO6862104A2 (es) | 2014-02-10 |
ES2641877T3 (es) | 2017-11-14 |
AU2012253896A1 (en) | 2013-11-21 |
JP2014515921A (ja) | 2014-07-07 |
BR112013028537A2 (pt) | 2017-01-17 |
RU2013148919A (ru) | 2015-06-20 |
AU2012253896B2 (en) | 2016-09-22 |
CA2835070A1 (en) | 2012-11-15 |
CN103648525B (zh) | 2016-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2013012905A (es) | Inmunotoxina recombinante dirigida a la mesotelina. | |
JO3486B1 (ar) | اتحادات مناعية مضادة للميزوثيلين واستخداماتها | |
PH12018500693A1 (en) | Pyrrolobenzodiazepine antibody drug conjugates and methods of use | |
TN2014000148A1 (en) | Antigen binding protein and its use as addressing product for the treatment of cancer | |
MX2016015176A (es) | Conjugacion especifica de sitio de farmacos enlazadores con anticuerpos y conjugados farmaco-anticuerpo (adc) resultantes. | |
WO2013072813A3 (en) | Cytotoxic peptides and antibody drug conjugates thereof | |
PH12019501330A1 (en) | Antibody drug conjugates for ablating hematopoietic stem cells | |
Lázaro-Gorines et al. | A novel carcinoembryonic antigen (CEA)-targeted trimeric immunotoxin shows significantly enhanced antitumor activity in human colorectal cancer xenografts | |
MX349306B (es) | Interferón de objetivo demuestra actividades potentes apoptóticas y antitumorales. | |
MX2011010469A (es) | Radicales de enlace al objetivo, armados con amatoxina para el tratamiento del cancer. | |
MX2016007865A (es) | Peptidos citotoxicos y conjugados de los mismos. | |
MX344009B (es) | Conjugados de amatoxinas con enlaces mejorados. | |
SA112330988B1 (ar) | أجسام مضادة تخص trop-2 واستخداماتها | |
NZ710929A (en) | Antibody drug conjugates | |
DK1180123T3 (da) | Immunkonjugater, der har höj bindingsaffinitet | |
PT2528625E (pt) | Pirrolobenzodiazepinas e conjugados das mesmas | |
MX2020010408A (es) | Conjugados de anticuerpo-farmaco y sus usos para el tratamiento del cancer. | |
PH12020551556A1 (en) | Drug conjugates of cmet monoclonal binding agents, and uses thereof | |
FR3096259B1 (fr) | conjugués anticorps-médicament et leur utilisation en thérapie | |
CY1126032T1 (el) | Συζευγματα αντισωματος-φαρμακου που στοχευουν uparap | |
WO2012075490A3 (en) | Anti-podoplanin antibodies and methods of use | |
MX2022012589A (es) | Metodos para conjugar un agente a un resto tiol en una proteina que contiene al menos un enlace trisulfuro. | |
UA114073C2 (uk) | Кон'югати піролбензодіазепіну для лікування проліферативних захворювань |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |